- Home
- MRSN vs KVAC Comparison
MRSN vs KVAC Comparison
Compare MRSN & KVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- KVAC
- Stock Information
- Founded
- MRSN 2001
- KVAC 2021
- Country
- MRSN United States
- KVAC United States
- Employees
- MRSN N/A
- KVAC N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- KVAC
- Sector
- MRSN Health Care
- KVAC
- Exchange
- MRSN Nasdaq
- KVAC Nasdaq
- Market Cap
- MRSN 252.0M
- KVAC 210.5M
- IPO Year
- MRSN 2017
- KVAC 2023
- Fundamental
- Price
- MRSN $1.86
- KVAC $10.94
- Analyst Decision
- MRSN Buy
- KVAC
- Analyst Count
- MRSN 6
- KVAC 0
- Target Price
- MRSN $6.00
- KVAC N/A
- AVG Volume (30 Days)
- MRSN 1.1M
- KVAC 12.1K
- Earning Date
- MRSN 11-13-2024
- KVAC 01-01-0001
- Dividend Yield
- MRSN N/A
- KVAC N/A
- EPS Growth
- MRSN N/A
- KVAC N/A
- EPS
- MRSN N/A
- KVAC 0.43
- Revenue
- MRSN $34,837,000.00
- KVAC N/A
- Revenue This Year
- MRSN N/A
- KVAC N/A
- Revenue Next Year
- MRSN N/A
- KVAC N/A
- P/E Ratio
- MRSN N/A
- KVAC $25.36
- Revenue Growth
- MRSN N/A
- KVAC N/A
- 52 Week Low
- MRSN $1.22
- KVAC $10.32
- 52 Week High
- MRSN $6.28
- KVAC $10.94
- Technical
- Relative Strength Index (RSI)
- MRSN 42.16
- KVAC 85.76
- Support Level
- MRSN $1.93
- KVAC $10.90
- Resistance Level
- MRSN $2.81
- KVAC $10.91
- Average True Range (ATR)
- MRSN 0.24
- KVAC 0.00
- MACD
- MRSN -0.05
- KVAC 0.00
- Stochastic Oscillator
- MRSN 7.79
- KVAC 100.00
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About KVAC Keen Vision Acquisition Corporation
Keen Vision Acquisition Corp is a blank check company.